Paasa Logo
BriaCell Therapeutics Corp. logo
BCTXNASDAQMarket closedOpens 9:30am ET

BriaCell Therapeutics Corp.

$4.28Last updated
+$0.20 (4.90%)Past day
Timezone

BriaCell Therapeutics Corp. (NASDAQ: BCTX) is trading at $4.28, about ₹411 at today's USD/INR rate, as of 30 Sep 2026, 4:00 PM ET, up 4.90% today. Indian residents can buy BriaCell Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$4.09
Previous close:$4.08
Volume:87.67K

Today's low

$4.01

Today's high

$4.34

52 week low

$2.60

52 week high

$14.68

BCTX opened at $4.09, closed previously at $4.08, and has traded between $2.60 and $14.68 over the past 52 weeks.

About

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.

Country
CA
CEO
William V. Williams
Exchange listed on
NASDAQ
Industry
Biotechnology
Base currency
USD
Full Time Employees
16
Sector
Healthcare
IPO date
14/03/2012

Key statistics

Avg. volume

268.39K

Market cap

$37.24M

P/E Ratio

-0.35

Price-to-sales ratio

0.00

Enterprise value

-$374.14K

Free cash flow yield

-278.02%

Debt-to-equity ratio

0.00

Return on equity

-148.44%

ROIC

-155.30%

Beta

1.52

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$0.00

Earnings per share

-$62.60

Free cash flow

-$39.07M

Net profit margin

0.00%

Gross margin

0.00%

EBITDA

-$37.58M

Revenue growth

0.00%

Similar securities

This is not an investment recommendation

How to buy BriaCell Therapeutics from India

Indian residents can buy BriaCell Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for BriaCell Therapeutics and place an order

    Find BriaCell Therapeutics by name or by its ticker, BCTX, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. BriaCell Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your BriaCell Therapeutics position in USD and INR. BriaCell Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in BriaCell Therapeutics from India

Trading and taxes when buying BriaCell Therapeutics from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneBriaCell Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy BriaCell Therapeutics stock?

Yes. BriaCell Therapeutics (BCTX) has been listed on NASDAQ since 2012, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one BriaCell Therapeutics share cost in rupees?

One BriaCell Therapeutics share is $4.28 — about ₹411 at a USD/INR rate of 96.00 on 30 Sep 2026. Both the BriaCell Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying BriaCell Therapeutics from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of BriaCell Therapeutics?

Yes. One BriaCell Therapeutics share is $4.28, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in BriaCell Therapeutics.

How are gains on BriaCell Therapeutics shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the BriaCell Therapeutics price. Paasa issues a capital-gains statement for your return.

Does BriaCell Therapeutics pay a dividend?

No. BriaCell Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade BriaCell Therapeutics from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is BriaCell Therapeutics a United States company, and does that change how it is taxed?

BriaCell Therapeutics trades on NASDAQ in US dollars, but the company is domiciled in Canada. BriaCell Therapeutics trades as an ordinary share listed directly in the US, not a depositary receipt. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Your India-side capital-gains treatment is the same either way.

Do I have to declare BriaCell Therapeutics shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your BriaCell Therapeutics holding, its cost and its closing value.

How do I sell BriaCell Therapeutics and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.